Protagonist Therapeutics, Inc. (PTGX)
144.33
-5.17
(-3.46%)
USD |
NASDAQ |
Aug 28, 16:00
144.30
-0.04
(-0.02%)
After-Hours: 20:00
Protagonist Therapeutics Cash from Operations (Quarterly) : 219.05M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 219.05M |
| March 31, 2026 | -48.94M |
| December 31, 2025 | -36.98M |
| September 30, 2025 | -1.937M |
| June 30, 2025 | -28.78M |
| March 31, 2025 | 125.36M |
| December 31, 2024 | -29.18M |
| September 30, 2024 | -27.86M |
| June 30, 2024 | 268.62M |
| March 31, 2024 | -27.43M |
| December 31, 2023 | 16.96M |
| September 30, 2023 | -26.61M |
| June 30, 2023 | -26.24M |
| March 31, 2023 | -34.35M |
| December 31, 2022 | -31.64M |
| September 30, 2022 | -25.20M |
| June 30, 2022 | -13.64M |
| March 31, 2022 | -37.67M |
| December 31, 2021 | -26.94M |
| September 30, 2021 | -28.47M |
| June 30, 2021 | -23.70M |
| March 31, 2021 | -28.76M |
| December 31, 2020 | -18.87M |
| Date | Value |
|---|---|
| September 30, 2020 | -16.30M |
| June 30, 2020 | -21.48M |
| March 31, 2020 | -15.85M |
| December 31, 2019 | -14.29M |
| September 30, 2019 | -14.25M |
| June 30, 2019 | 3.67M |
| March 31, 2019 | -16.66M |
| December 31, 2018 | -10.14M |
| September 30, 2018 | -9.276M |
| June 30, 2018 | -15.40M |
| March 31, 2018 | -15.14M |
| December 31, 2017 | -14.15M |
| September 30, 2017 | 40.70M |
| June 30, 2017 | -12.33M |
| March 31, 2017 | -10.36M |
| December 31, 2016 | -9.68M |
| September 30, 2016 | -6.98M |
| June 30, 2016 | -8.073M |
| March 31, 2016 | -5.239M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | -2.433M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| AbbVie, Inc. | 3.436B |
| Gilead Sciences, Inc. | 3.573B |
| Johnson & Johnson | 8.616B |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
| BioMarin Pharmaceutical, Inc. | 168.11M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.43M |
| Cash from Financing (Quarterly) | 9.743M |
| Free Cash Flow | 130.58M |
| Free Cash Flow Per Share (Quarterly) | 3.083 |
| Free Cash Flow to Equity (Quarterly) | 219.44M |
| Free Cash Flow to Firm (Quarterly) | 218.88M |
| Free Cash Flow Yield | 1.34% |